BRAF<sup>wild</sup> papillary thyroid carcinoma has two distinct mRNA expression patterns with different clinical behaviors.
other · Level V
Where this comes from
- Record sourced from PubMed, PMID 29573027.
- Also identified by DOI 10.1002/hed.25151.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Using a large set of genomic data from The Cancer Genome Atlas (TCGA), we classified BRAF<sup>wild</sup> papillary thyroid carcinomas (PTCs) into 2 subtypes with distinct molecular patterns and different clinical behaviors. We also suggested gene signatures (RAS-score) to predict molecular subtypes and clinical behaviors of BRAF<sup>wild</sup> PTC. Integrated genomic analysis was done using all genomic data of PTC in TCGA data portal (https://tcga-data.nci.nih.gov) and cancer browser (https://genome-cancer.ucsc.edu). Using Gene Ontology and a logistic regression test, we selected gene signatures (RAS-score) and applied this prediction model to the validation cohort (GSE60542). When we performed multiplatform genomic analysis, BRAF<sup>wild</sup> PTCs were divided into 2 molecular subtypes. Each subtype showed distinct molecular patterns and clinical behaviors. Gene signatures successfully predicted molecular subtype in another validation cohort. We found that BRAF<sup>wild</sup> PTCs were divided into 2 molecular subtypes and each subtype showed distinct molecular patterns, different activated pathways, and different clinical behaviors.
Medical subject headings
- Mutation
- Proto-Oncogene Proteins B-raf
- RNA, Messenger
- Thyroid Cancer, Papillary